Prospective Validation of a Points Score System Predicting 30-day Survival

Description

This is a one-stage single-arm phase II clinical trial designed to prospectively test the survival prediction tool as developed by Lee et al on patients referred to radiation oncology for palliative treatments. Survival prediction score based on objective data including laboratory values, attendance to emergency room, and primary cancer origin will be assigned to each patient at time of enrollment.

Conditions

Metastatic Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a one-stage single-arm phase II clinical trial designed to prospectively test the survival prediction tool as developed by Lee et al on patients referred to radiation oncology for palliative treatments. Survival prediction score based on objective data including laboratory values, attendance to emergency room, and primary cancer origin will be assigned to each patient at time of enrollment.

Prospective Validation of a Points Score System Predicting 30-day Survival for Patients With Metastatic Cancer Receiving Palliative Radiation Therapy

Prospective Validation of a Points Score System Predicting 30-day Survival

Condition
Metastatic Cancer
Intervention / Treatment

-

Contacts and Locations

Avon

IU Health West, Avon, Indiana, United States, 46123

Carmel

IU Health North / Schwarz Cancer Center, Carmel, Indiana, United States, 46032

Indianapolis

Indiana University Health Hospital, Indianapolis, Indiana, United States, 46202

Indianapolis

Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States, 46202

Indianapolis

Methodist Hospital, Indianapolis, Indiana, United States, 46202

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Age ≥ 18 at time of consent
  • 2. Ability to provide written informed consent
  • 3. Cancer diagnosis referred to Radiation Oncology for palliative radiation therapy
  • 4. Patients who either choose to not receive radiation therapy or not recommended to receive radiation therapy will remain eligible
  • 5. Those patients who undergo a course of palliative radiation therapy, it is not the requirement of this study to complete that course of treatment. Those who prematurely end their course of treatment will remain eligible Note: Patients who ultimately either choose to not receive radiation or not recommended to receive radiation will remain eligible
  • 1. Patients who are unable to participate in follow up visits per investigator discretion (virtual/phone follow up is permitted)
  • 2. Patients who are receiving definitive/curative course of radiation therapy
  • 3. Patients who self-report as pregnant or nursing

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Indiana University,

Naoyuki Saito, MD PhD, PRINCIPAL_INVESTIGATOR, Indiana University

Study Record Dates

2025-12